HIV Management: Clinical Case Conundrums

1.75 CME
1.75 CPE
105 MINS
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact



Provider Statement

This continuing education activity is provided by Vindico Medical Education

Support Statement

This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Activity Description

Antiretroviral therapy has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already diverse field of HIV treatment. Clinicians must keep apprised of new data regarding treatment strategies, including drug simplification and long-acting injectables, selection of appropriate individualized therapy, and effective management of treatment side effects. In this interactive, case-based program, expert faculty will provide guidance on how to incorporate new treatment strategies into clinical practice. They will also discuss various aspects of HIV management, including the selection of an initial antiretroviral regimen for a patient, treatment modification in highly treatment-experienced patients with multiple comorbidities, and treatment of HIV in pregnant patients.

Target Audience

The intended audience for this activity is infectious disease specialists, pharmacists, and other health care professionals involved in the management of patients with human immunodeficiency virus.

Learning Objective(s)

Upon successful completion of this educational activity, participants should be better able to:

  • Incorporate new evidence-based guidelines for the use of antiretroviral (ARV) agents in adults and adolescents with HIV.
  • Initiate treatment in ARV-naive patients based on individual patient needs, characteristics, preferences, and genotypic drug-resistance testing.
  • Interpret recent evidence regarding the use of antiretroviral therapy (ART) in women of childbearing potential.
  • Incorporate the use of switching ART regimens in patients who have experienced adverse events.
  • Implement the most appropriate regimens in patients with HIV and comorbidities.
  • Recognize the complexities of HIV management in older, highly treatment-experienced patients due to polypharmacy, drug-drug interactions, and other issues.

Activity Chair

Paul E. Sax, MD
Clinical Director, Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, MA


Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Investigator, Lundquist Institute
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Joseph J. Eron, Jr., MD
Professor of Medicine
Division of Infectious Diseases
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, NC

Charlotte-Paige Rolle, MD, MPH
Adjunct Assistant Professor of Global Health
Emory Rollins School of Public Health
Atlanta, GA
Director of Research Operations
Orlando Immunology Center
Orlando, FL


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico  Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 1.75  contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-20-012-H02-P, effective 11/18/2020. This is a knowledge-based activity and there is no fee to attend.

This enduring material is approved for 1 year from the date of original release, November 18, 2020, through November 17, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME/CPE activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 6 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or an ACPE Statement of Credit. Vindico will report pharmacist learners to CPE monitor within 30 days of completion of the activity.

MIPS Qualifying Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.
To meet the criteria for improvement activities in the Merit-based Incentive Payment System (MIPS) of Quality Payment Program (QPP), accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.


In accordance with the Accreditation Council for Continuing Medical Education and Accreditation Council for Pharmacy Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers, and staff involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.

Activity Chair and Faculty report the following relationship(s)

Eric S. Daar, MD
Consulting Fee: Genentech, Gilead, Merck
Contracted Research: Gilead, Merck, ViiV

Joseph J. Eron, Jr., MD
Consulting Fee: Gilead, Merck, ViiV
Contracted Research (Paid to institution): Gilead, Janssen, ViiV

Charlotte-Paige Rolle, MD, MPH
Consulting Fee: ViiV
Speakers Bureau: ViiV
Contracted Research: Gilead, Janssen, ViiV

Paul E. Sax, MD
Consulting Fee: Gilead, GlaxoSmithKline/ViiV, Janssen, Merck
Contracted Research: Gilead, GlaxoSmithKline/ViiV, Merck
Editorial Positions: Medscape, NJEM Journal Watch, Open Forum Infectious Diseases, UpToDate

Reviewers report the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Contracted Research (paid to Institution): ViiV

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME/CPE  Questions?

Contact us at